Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus

NCT00539838 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00539838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00539838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus
Lead sponsor
Genentech, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
December 19, 2007
Completion date
July 12, 2011
Enrollment
33 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus